| Inhibition of human CYP3A4 - BioAssay Summary Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats. ..more |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compound: Description: Title: Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure. Abstract: Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats. (PMID: 21873051) Categorized Comment ChEMBL Assay Type: ADMET ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 17045 ChEMBL target type: Target is a single protein chain Result Definitions
* Activity Concentration. Data Table (Concise) Classification
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||